Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech

Intuitive Surgical (ISRG) is down ~40% from its early-2025 peak and trades at a lofty 42x P/E, but the core demand and installed base remain intact. Da Vinci systems in use rose 12% YoY to 11,710, while Q2’26 procedures grew 16% YoY and Q2 system sales increased to 468 from 395. Competition from Medtronic’s Hugo (approved late-2025) and J&J’s OTTAVA (approved mid-2026) is expected to be limited to specific surgery niches, and ISRG’s revenue mix is more resilient than system sales alone (only ~25% from new systems; ~75% from services/instruments), supporting recurring cash flow.

Analysis

The near-term market mistake is to model this as a share-loss story when the bigger mechanism is multiple compression. ISRG’s recurring instruments/services mix makes earnings less sensitive to unit placements than headline robot sales imply, so competition should show up first in valuation and growth-duration anxiety, not an abrupt revenue cliff. That means the stock can stay volatile for months even if fundamentals remain intact; the first real tell is not robot approval headlines, but whether procedure growth and consumables attach rate decelerate for 2-3 quarters.

For MDT and JNJ, the robot franchises are likely option value rather than immediate P&L drivers. Penetration in a capital-intensive workflow requires training, surgeon preference, and installed-base inertia, so the early phase is more about spending to gain credibility than harvesting profit. Second-order, that can pressure medtech margins and ROIC before any meaningful competitive displacement of ISRG; the market may be underestimating the earnings dilution embedded in winning the bidding war.

Contrarian view: consensus is too binary on “winner takes all.” Surgical robotics is probably a multi-player market, but that does not automatically make the incumbents cheap; the issue is whether ISRG’s historical premium can remain intact if growth normalizes. The thesis is falsified if procedures growth drops into low double digits or if competitive launches start taking share in the highest-utilization specialties sooner than expected over the next 1-2 quarters.

Key Decisions for Investors

• Stay constructive on ISRG only on further weakness; treat the current drawdown as a multiple reset, not a thesis break. Best entry is on any post-earnings selloff where procedure growth remains >12% and the stock trades closer to low-30s forward earnings; if procedures slow below that, the de-rating can persist.
• Do not chase MDT or JNJ for near-term robotics upside. Their competitive launches are more likely to be margin-dilutive in the first 12 months than accretive, so use any rally tied to launch excitement to fade strength rather than buy the optionality outright.
• Tactical pair: long ISRG / short MDT into any broad medtech strength, sized modestly. The relative edge is that ISRG monetizes utilization immediately through instruments/services, while MDT’s payoff depends on a slower adoption curve; stop if MDT commentary shows faster-than-expected procedure conversion or if ISRG procedure growth slips below 10%-12%.
• Set a catalyst watch on the next two quarterly prints for ISRG procedure growth, system placements, and instrument revenue per case. If recurring revenue growth stays resilient while placements soften, the competitive threat is probably overestimated and the multiple can re-rate back up over 6-12 months.